Tonix closes in on the first new fibromyalgia drug in more than a decade

In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.

By Kelly Bilodeau • Jan. 29, 2024

‘1 plus 1 equals 3’ — the co-CEO model in pharma

Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

By Meagan Parrish • Jan. 26, 2024

Explore the Trendline➔

Cell and gene therapies

How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

By PharmaVoice staff

The biggest questions hanging over pharma in 2024

Key trends on the horizon in the life sciences this year.

By Meagan Parrish • Jan. 25, 2024

King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

By Michael Gibney • Jan. 25, 2024

The hunt for an elusive universal coronavirus vaccine

A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

By Alexandra Pecci • Jan. 22, 2024

Controversial challenge trials offer unparalleled innovation — with ethical bumps

Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.

By Kelly Bilodeau • Jan. 22, 2024

Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

By Meagan Parrish • Jan. 19, 2024

How to make 2024 a banner year for biopharma, despite the headwinds

Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.

By Michael Gibney • Jan. 18, 2024

An enduring COVID mystery: Why some do fine and others die

The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

By Alexandra Pecci • Jan. 17, 2024

Pharma takes a gut check of microbiome drugs

On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

By Kelly Bilodeau • Jan. 16, 2024

4 big FDA approval dates to watch in 2024

Following a year where the FDA approved 55 new drugs, the 2024 PDUFA calendar is set with a number of potentially buzzy approvals. 

By Alexandra Pecci • Jan. 12, 2024

Pharma execs sound off on trends and policies they’re tracking in 2024

From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

By Meagan Parrish • Jan. 12, 2024

PharmaVoice’s Crystal Ball: Perspectives on the financial future

Industry leaders predict what it will take for pharma to defeat its financial foes in 2024.

By Meagan Parrish • Jan. 9, 2024

Year of biotech layoffs leaves industry looking for spark

Small and mid-sized drugmakers shed at least 10,000 jobs in 2023, according to data compiled by BioPharma Dive, but recent deal, stock market momentum have brought some optimism.

By Delilah Alvarado , Ned Pagliarulo • Jan. 8, 2024

Regulatory twists and turns are coming for biopharma in 2024

New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

By Kelly Bilodeau • Jan. 8, 2024

In the post-pandemic era, three players still dominate the infectious disease market

While key companies maintain their grip on the space, emerging infectious disease focus areas and a handful of other players are augmenting the market.

By Alexandra Pecci • Jan. 5, 2024

Pharma’s financial market will be a tale of two cities in 2024

What can the industry expect in 2024? Some bright spots, a few bumps and “immaculate disinflation.”

By Kelly Bilodeau • Jan. 4, 2024

Alzheimer’s research is hot, but successful patient recruitment will determine its future

Key strategies for bringing more patients into the clinical trial fold.

By Kelly Bilodeau • Jan. 4, 2024

10 of our most read articles in 2023

A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

By Meagan Parrish • Dec. 22, 2023

As ALS research booms, one treatment center finds itself in the spotlight

The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.

By Jacob Bell • Dec. 22, 2023

Biopharma’s FTC headache deepens with guideline shifts years in the making

Closer scrutiny of pharma deals has made the M&A landscape trickier as a new approach seeks to expand the competitive arena.

By Michael Gibney • Dec. 21, 2023

5 noteworthy pharma AI investments in 2023

The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.

By Alexandra Pecci • Dec. 19, 2023

This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain

Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.

By Michael Gibney • Dec. 19, 2023

Rise of the chief investment officer: Why the unique role works for Roivant

Dr. Mayukh Sukhatme, president and chief investment officer for Roivant, discusses the long game of partnering and business deals in biopharma.

By Alexandra Pecci • Dec. 18, 2023

Babson gets one step closer to delivering on Theranos-like blood testing

A recent FDA clearance could pave the way to pin-prick blood tests at local pharmacies and potentially one day, clinical trials.

By Kelly Bilodeau • Dec. 18, 2023